BIOLINERX LTD/S (NASDAQ:BLRX) – Analysts at Oppenheimer raised their FY2023 earnings estimates for BIOLINERX LTD/S in a research report issued to clients and investors on Tuesday, May 14th. Oppenheimer analyst M. Breidenbach now expects that the biotechnology company will post earnings per share of $0.14 for the year, up from their prior forecast of $0.13. Oppenheimer has a “Buy” rating on the stock.
BIOLINERX LTD/S (NASDAQ:BLRX) last released its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05).
NASDAQ:BLRX opened at $0.36 on Thursday. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.12 and a quick ratio of 4.74. BIOLINERX LTD/S has a 52-week low of $0.35 and a 52-week high of $1.84.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. ETF Managers Group LLC increased its position in BIOLINERX LTD/S by 79.4% during the fourth quarter. ETF Managers Group LLC now owns 375,909 shares of the biotechnology company’s stock worth $164,000 after buying an additional 166,386 shares during the last quarter. Delek Group Ltd. acquired a new position in BIOLINERX LTD/S during the first quarter worth approximately $92,000. Menta Capital LLC acquired a new position in BIOLINERX LTD/S during the fourth quarter worth approximately $33,000. Deutsche Bank AG acquired a new position in BIOLINERX LTD/S during the fourth quarter worth approximately $26,000. Finally, Two Sigma Securities LLC acquired a new position in BIOLINERX LTD/S during the fourth quarter worth approximately $25,000. 33.72% of the stock is currently owned by hedge funds and other institutional investors.
About BIOLINERX LTD/S
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Recommended Story: What Does Beta Mean In Stock Selection
Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.